The advent of tyrosine kinase inhibitors (TKIs), which target the adenosine triphosphate (ATP) binding site of ABL1, has transformed CML into a chronic disease; many patients achieve a life expectancy close to that of the general population [3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.